基于深度学习建立口腔癌肿瘤出芽量化评估模型的双向队列研究

注册号:

Registration number:

ChiCTR2500107135 

最近更新日期:

Date of Last Refreshed on:

2025-08-05 08:45:00 

注册时间:

Date of Registration:

2025-08-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于深度学习建立口腔癌肿瘤出芽量化评估模型的双向队列研究

Public title:

A two-way cohort Study on establishing a deep learning-based model of quantification of tumor budding in oral cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于深度学习建立口腔癌肿瘤出芽量化评估模型的双向队列研究

Scientific title:

A two-way cohort Study on establishing a deep learning-based model of quantification of tumor budding in oral cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李德龙 

研究负责人:

李德龙 

Applicant:

Li Delong 

Study leader:

Li Delong 

申请注册联系人电话:

Applicant telephone:

+86 18611256216

研究负责人电话:

Study leader's
telephone:

+86 10 57099437

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ldl11000@126.com

研究负责人电子邮件:

Study leader's E-mail:

ldl11000@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市丰台区樊家村路9号

研究负责人通讯地址:

中国北京市丰台区樊家村路9号院

Applicant address:

No.9 Fanjiacun Road, FengTai District, Beijing, China

Study leader's address:

No.9 Fanjiacun Road, Fengtai District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京口腔医院

Applicant's institution:

Beijing Stomatological Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京口腔医院

Affiliation of the Leader:

Beijing Stomatological Hospital , Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CMUSH-IRB-KJ-PJ-2025-05

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京口腔医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Stomatological Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-21 00:00:00

伦理委员会联系人:

夏晓钰

Contact Name of the ethic committee:

Xia Xiaoyu

伦理委员会联系地址:

中国北京市丰台区樊家村路9号院

Contact Address of the ethic committee:

No.9 Fanjiacun Road, Fengtai District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 57099307

伦理委员会联系人邮箱:

Contact email of the ethic committee:

18602615270@163.com

研究实施负责(组长)单位:

首都医科大学附属北京口腔医院

Primary sponsor:

Beijing Stomatological Hospital , Capital Medical University

研究实施负责(组长)单位地址:

中国北京市丰台区樊家村路9号院

Primary sponsor's address:

No.9 Fanjiacun Road, Fengtai District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京口腔医院

具体地址:

中国北京市丰台区樊家村路9号院

Institution
hospital:

Beijing Stomatological Hospital , Capital Medical University

Address:

No.9 Fanjiacun Road, Fengtai District, Beijing, China

经费或物资来源:

首都医科大学附属北京口腔医院创新基金

Source(s) of funding:

Innovation Foundation of Beijing Stomatological Hospital, Capital Medical University

研究疾病:

口腔鳞状细胞癌  

Target disease:

Oral squamous cell carcinoma (OSCC)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1)建立口腔癌患者的回顾性和前瞻性双向研究队列,获取和分析临床基线数据和病理图像数据,构建和验证基于病理图像数据的肿瘤出芽结构分割识别和量化评估深度学习模型。 (2)基于建立的口腔癌病理肿瘤出芽量化评估模型,结合随访数据,精确分析肿瘤出芽水平与口腔癌患者长期预后的相关性,为口腔鳞癌精准医疗和决策制定提供循证医学证据。  

Objectives of Study:

(1) Establish an ambidirectional cohort (retrospective and prospective) of oral cancer patients, collect and analyze clinical baseline data and pathological image data, then develop and validate a deep learning model for segmentation recognition and quantitative assessment of tumor budding structures based on pathological imaging.​​ ​​(2) Utilizing the established quantitative assessment model for pathological tumor budding in oral cancer, conduct precision analysis of the correlation between tumor budding levels and long-term prognosis in patients, combined with follow-up data, to provide evidence-based medical evidence for precision medicine and clinical decision-making in oral squamous cell carcinoma (OSCC).​

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

回顾组: 1.无法获取研究所需的完善临床资料者; 2.处于妊娠期或哺乳期的女性; 3.精神障碍或智力障碍者; 前瞻组: 1.无法获取研究所需的完善临床资料者; 2.处于妊娠期或哺乳期的女性; 3.精神障碍或智力障碍者; 4.患有无法手术的严重并存疾病者; 5.因个人意愿拒绝治疗方案者;

Exclusion criteria:

Review group: 1.Subjects for whom sufficient clinical data required by the study cannot be obtained.​; 2.Pregnant or lactating women.​; 3.Individuals with psychiatric disorders or intellectual disabilities.​​; Prospective group: 1.Subjects for whom sufficient clinical data required by the study cannot be obtained.​; 2.Pregnant or lactating women.​; 3.Individuals with psychiatric disorders or intellectual disabilities.​​; 4.Individuals with severe comorbidities contraindicating surgery.​​; 5.Individuals declining the treatment regimen based on personal preference.​​;

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-07 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

前瞻性队列组

样本量:

150

Group:

prospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

N

Intervention code:

组别:

回顾性队列组

样本量:

250

Group:

Retrospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京口腔医院 

单位级别:

三甲 

Institution
hospital:

Beijing Stomatological Hospital , Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肿瘤出芽

指标类型:

主要指标

Outcome:

Tumor budding

Type:

Primary indicator

测量时间点:

术后第7天

测量方法:

肿瘤出芽水平:对每例入组患者,由两位或以上经严格培训的医师进行人工判读,并以平均值作为该患者的肿瘤出芽水平。记录模型每次迭代后评估的每位患者的肿瘤出芽水平,作为模型验证的依据。

Measure time point of outcome:

The 7th day postoperative

Measure method:

Tumor Budding Level Assessment: For each enrolled patient, the tumor budding level was manually assessed by two or more rigorously trained pathologists, with the average value recorded as the final result. The tumor budding level of each patient evaluated after every model iteration was documented as the basis for model validation.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 30 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本试验设有试验记录本及病例报告表,在试验记录本上记录本研究中试验过程和试验结果以及招募过程中受试者参与研究意愿。所有数据将由课题负责人及时、真实、准确、完整的记录在试验记录本和病例报告表内,并由课题负责人负责管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Trial documentation shall include both a Trial Master Record and Case Report Forms (CRFs). The Trial Master Record shall document the experimental procedures, results, and subjects' willingness to participate during recruitment. All data must be recorded promptly, truthfully, accurately, and completely by the Principal Investigator in the Trial Master Record and CRFs, with the Principal Investigator responsible for their management. ​​​Electronic data files (e.g., scanning image data, databases, inspection programs, analytical procedures, analysis results, codebooks, and documentation) shall be classified and stored with dual backups on separate disks or recording media, ensuring secure preservation against damage.​​

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-08-05 08:44:53